Q1 Earnings Forecast for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Stock analysts at Leerink Partnrs raised their Q1 2025 earnings per share estimates for shares of Illumina in a research note issued to investors on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now forecasts that the life sciences company will post earnings of $0.85 per share for the quarter, up from their prior forecast of $0.84. The consensus estimate for Illumina’s current full-year earnings is $4.11 per share.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same period in the previous year, the firm posted $0.33 EPS. The business’s revenue was down 3.5% on a year-over-year basis.

A number of other analysts also recently weighed in on ILMN. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price on the stock in a research report on Thursday, October 17th. Leerink Partners upped their price objective on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Canaccord Genuity Group lifted their target price on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a report on Tuesday, November 5th. UBS Group raised their price objective on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, Citigroup downgraded Illumina from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $190.00 to $165.00 in a report on Wednesday, December 11th. Eight equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Illumina presently has an average rating of “Moderate Buy” and an average price target of $165.95.

Illumina Price Performance

Shares of ILMN stock opened at $139.68 on Thursday. The business’s fifty day moving average is $141.46 and its 200 day moving average is $132.03. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The stock has a market cap of $22.15 billion, a price-to-earnings ratio of -14.02 and a beta of 1.11. Illumina has a twelve month low of $100.08 and a twelve month high of $156.66.

Institutional Investors Weigh In On Illumina

Institutional investors and hedge funds have recently bought and sold shares of the business. Versant Capital Management Inc raised its stake in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the period. TD Private Client Wealth LLC raised its position in shares of Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after buying an additional 141 shares during the last quarter. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after buying an additional 168 shares in the last quarter. Private Trust Co. NA boosted its position in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after acquiring an additional 212 shares during the last quarter. Finally, Focused Wealth Management Inc purchased a new position in Illumina during the third quarter valued at $63,000. 89.42% of the stock is owned by institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.